AzTrials
AzTrials

Ischemic Heart DiseaseIMPACT-FFRNCT03030495

Registry of Comprehensive Imaging and Physiological Evaluation of Deferred Lesions Based on FFR

An observational study of Ischemic Heart Disease, run by Samsung Medical Center at 4 sites in South Korea.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

1. To compare the risk of atherosclerotic lesion progression and subsequent patient-oriented composite outcomes (all-cause mortality, any MI, or any Ischemia-driven repeat revascularization) between deferred lesions with or without over microvascular disease, defined as physiological classification 2. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Ischemic Heart Disease
What is being tested?
Comprehensive physiologic evaluation and Intravascular imaging devices
Type of treatment
Medical device
How many people
1,400 participants
Where
4 sitesSouth Korea
Study dates
1 Dec 2016to 31 Dec 2025
How long will I take part?
5 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with intermediate degree of stenosis (30-70% stenosis by visual estimation) with fractional flow reserve of >0.80 in major epicardial coronary artery amenable to stent implantation or vessel size ≥2.5 mm.

Who may be able to join

  • Subject must be ≥ 18 years
  • Patients suspected with ischemic heart disease
  • Patients with intermediate degree of stenosis (30-70% stenosis by visual estimation) with fractional flow reserve of >0.80 in major epicardial coronary artery amenable to stent implantation or vessel size≥2.5 mm
  • Patients whose coronary stenosis were evaluated by invasive imaging techniques (intravascular ultrasound and optical coherence tomography) and physiologic assessment (coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve)
  • Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic or imaging evaluation and he/she or his/her legally authorized representative provides written informed consent to any study related procedure

Who cannot join

  • End-staged renal disease on peritoneal dialysis or hemodialysis (estimated GFR < 15mL/min)
  • Acute hepatic injury
  • Cardiogenic shock (systolic blood pressure < 90mmHg or requiring inotropics to maintain blood pressure > 90mmHg)
  • The patient has a known hypersensitivity or contraindication to any of the following medications: statin, ezetimibe, heparin, aspirin, clopidogrel, prasugrel, ticagrelor
  • Non-cardiac co-morbid conditions are present with life expectancy <2 year (per site investigator's medical judgment)
  • Unable to perform invasive imaging study (intravascular ultrasound and optical coherence tomography) or physiologic assessment (coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve)

Trial locations and contacts

4 sites in 1 country.

South Korea4 sites
  • Keimyung University Dongsan Medical Center

    Daegu

  • Inje University Ilsan Paik Hospital

    Goyang-si

  • Samsung Medical Center

    Seoul

  • Seoul National University Hospital

    Seoul

Other trials in South Korea

About this study

Official title: IMaging and Physiologic Predictors of Atherosclerotic Progression in Deferred Lesions With Contemporary Medical Treatment Based on Fractional Flow Reserve-guided Strategy

  1. To compare the risk of atherosclerotic lesion progression and subsequent patient-oriented composite outcomes (all-cause mortality, any MI, or any Ischemia-driven repeat revascularization) between deferred lesions with or without over microvascular disease, defined as physiological classification
  2. To explore independent predictors of atherosclerotic lesion progression in deferred lesions based on fractional flow reserve-guided strategy and treated by contemporary medical treatment
Read the detailed description

The coronary artery system has 3 components with different functions: conductive epicardial coronary arteries, arterioles, and capillaries. When any one of these systems fails, myocardial ischemia can occur. Therefore, the presence of epicardial coronary artery stenosis is not necessarily a prerequisite for ischemic heart disease (IHD). Although it has not been established that microvascular disease is independent of macrovascular disease, clinical studies have consistently shown that the presence of microvascular disease is an independent predictor of poor clinical outcomes, especially in patients with acute myocardial infarction (MI).

The pressure-derived fractional flow reserve (FFR) index has become a standard invasive method to evaluate the functional significance of epicardial coronary artery stenosis, and clinical outcomes of FFR-guided percutaneous coronary intervention (PCI) have proven to be better than those of angiography-guided PCI or medical treatment. Although FFR-guided PCI has been reported to improve patient outcomes and FFR is now regarded as the gold-standard invasive method to assess the functional significance of coronary artery stenosis, there is still room for further improvement in the diagnosis and treatment of patients with high FFR. In the FAME II study, 14.6% of the registry arm (FFR > 0.80 and deferral of PCI) experienced persistent angina, and 9.0% of these patients had clinical events during a 2-year follow-up period.

Therefore, microvascular assessment using coronary flow reserve (CFR) and the index of microcirculatory resistance (IMR) can provide additional diagnostic and prognostic insights for IHD patients, especially in those with high FFR.

Recently, Lee et al. (JACC 2016) investigated clinical outcomes among patients with high-FFR and deferred revascularization, according to physiologic classification using CFR and IMR. Lee et al. firstly presented that 7.0% of patients with high FFR had high IMR and low CFR and were regarded as having overt microvascular disease. Although the proportion of patients with high FFR who had overt microvascular disease was small, Group D had the poorest clinical outcomes during follow-up. The presence of overt microvascular disease was an independent prognostic factor in patients with high FFR. In addition, the presence of overt microvascular disease had additive prognostic value aside from clinical risk factors, with significantly improved discriminant function of the prediction model. These results suggest that the invasive physiologic assessment for microvascular disease combined with CFR and IMR can help identify patients at high risk for future cardiovascular events among those with high FFR.

Previous studies have shown that the presence of microvascular disease is associated with a higher risk of cardiovascular events such as cardiac death, MI, or revascularization in patients without flow-limiting epicardial stenosis. Several mechanisms have been proposed for the association of microvascular disease and poor clinical outcomes. In addition to myocardial ischemia, microvascular disease is reported to be associated with endothelial dysfunction and inflammatory activity that precedes intimal thickening, lipid deposition in the macrovascular system, and coronary vasomotor dysfunction. In a study by Dhawan et al., coronary microvascular dysfunction in patients with non-obstructive coronary artery disease was associated with higher serum high-sensitivity C-reactive protein and a higher frequency of thin-cap fibroatheroma.

In the Lee et al.'s study, the higher clinical event rates in patients with overt microvascular disease resulted from cardiac death and revascularization rates higher than those of the other groups. These results imply that the presence of overt microvascular disease can induce accentuated atherosclerotic progression and subsequent clinical events including cardiac death and ischemia-driven repeat revascularization.

Therefore, the IMaging and Physiologic Predictors of Atherosclerotic Progression in Deferred Lesions with Contemporary Medical Treatment based on Fractional Flow Reserve-guided Strategy (IMPACT-FFR registry) was designed to compare the risk of atherosclerotic plaque progression and subsequent clinical events between deferred lesions with or without over microvascular disease, defined as physiological classification and also to explore independent predictors of atherosclerotic lesion progression in deferred lesions based on fractional flow reserve-guided strategy and treated by contemporary medical treatment.

Being tested
Comprehensive physiologic evaluation, Intravascular imaging devices
Keywords
Ischemic Heart Disease, Stable angina, Fractional flow reserve, Index of Microcirculatory Resistance, Coronary Flow Reserve, Intravascular Imaging
Medical subject headings
Myocardial Ischemia, Angina, Stable

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Comprehensive physiologic evaluationDevice

    Also called Comprehensive physiologic evaluation using pressure-temperature sensor wire

    Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance

  • Intravascular imaging devicesDevice

    Also called Intravascular ultrasound or optical coherence tomography

    Intravascular ultrasound or optical coherence tomography

Study groups in NCT03030495
Study groupRoleWhat they receive
Overt microvascular diseaseFractional flow reserve>0.80, coronary flow reserve<2 \& Index of microvascular resistance>25U
Receives: Device: Comprehensive physiologic evaluation; Device: Intravascular imaging devices
No Overt microvascular diseaseFractional flow reserve>0.80, coronary flow reserve>2 \& Index of microvascular resistance<25U
Receives: Device: Comprehensive physiologic evaluation; Device: Intravascular imaging devices

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. patient-oriented composite outcome

    a composite of all-cause death, MI, any repeat revascularization

    Measured: 24 months

Secondary outcomes (15)
  1. patient-oriented composite outcome

    a composite of all-cause death, MI, any repeat revascularization

    Measured: 12 months

  2. patient-oriented composite outcome

    a composite of all-cause death, MI, any repeat revascularization

    Measured: 60 months

  3. All-cause death

    All-cause death

    Measured: 24 months

  4. cardiac death

    cardiac death

    Measured: 24 months

  5. Target-vessel nonfatal MI

    Target-vessel nonfatal MI

    Measured: 24 months

  6. Non-target vessel nonfatal MI

    Non-target vessel nonfatal MI

    Measured: 24 months

  7. All-cause nonfatal MI

    All-cause nonfatal MI

    Measured: 24 months

  8. Seattle Angina Questionnaires

    Angina severity measured with Seattle Angina Questionnaires

    Measured: 24 months

  9. Change in normalized total atheroma volume

    TAVnormalized = [Σ (EEM CSA - lumen CSA) / no. of images in pullback images in cohort] X median no. of images in cohort

    Measured: 12 months

  10. Change in total atheroma volume index

    Indexed total atheroma volume (TAVi): Σ(EEM CSA -lumen CSA)/plaque length

    Measured: 12 months

  11. Change in fibrous cap thickness by OCT

    Change in fibrous cap thickness by OCT at 12-month

    Measured: 12 months

  12. Change in Plaque burden at minimum lumen area site

    Change in Plaque burden at minimum lumen area site at 12-month Plaque burden = (EEM-MLA)/EEM x 100

    Measured: 12 months

  13. Change in Fractional flow reserve

    Change in Fractional flow reserve at 12-month

    Measured: 12 months

  14. Change in coronary flow reserve

    Change in coronary flow reserve at 12-month

    Measured: 12 months

  15. Change in index of microcirculatory resistance

    Change in index of microcirculatory resistance at 12-month

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jan 2017 (estimated)
  2. Study start1 Dec 2016
  3. Primary completion31 Dec 2025 (estimated)
  4. Study completion31 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,400 participants (estimated)
Target duration
5 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT03030495
Sponsor's protocol ID
IMPACT16453143
Acronym
IMPACT-FFR
Status last verified
May 2025
First submitted
20 Dec 2016
Last updated
15 May 2025
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Yes: After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked

Questions about this trial

What is this clinical trial studying?

An observational study of Ischemic Heart Disease, run by Samsung Medical Center at 4 sites in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 15 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

patient-oriented composite outcome (time frame: 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in